US Edition
News from pharmaceutical-technology.com
Information about Pharmaceutical-technology.com
Where is Pharmaceutical-technology.com located?Pharmaceutical-technology.com's WebsiteMedia Bias Ratings
Do you disagree?
Edit bias
Learn more about Media Bias Ratings.
Factuality
Learn more about Factuality Ratings
Reveal Factuality Ratings by upgrading to a Premium account.
Tap Upgrade to explore subscription options to meet all your reading needs.
Ownership
Learn more about Ownership categories
Reveal Ownership Data by upgrading to a Vantage account.
Tap Upgrade to explore subscription options to meet all your reading needs.
Top Pharmaceutical-technology.com News
Pharma · United StatesUS President Donald Trump said on Oct 16 that the price of Novo Nordisk’s best-selling weight-loss drug would be lowered and that negotiations over price changes would be swift.See the Story
Trump says price of weight-loss drug Ozempic will be lowered in the US
38% Right coverage: 29 sources
TechnologyAcquisition focused on lead clinical-stage program ICT01 in acute myeloid leukemia, where data from the ongoing Phase I/II EVICTION trial showed high treatment response ICT01 has the potential to be a new standard of care in combination in first line unfit acute myeloid leukemia, an aggressive blood cancer affecting older adults Ipsen to acquire all issued and outstanding shares of ImCheck Therapeutics, for which ImCheck Therapeutics' shareholde…See the Story
Ipsen to acquire ImCheck Therapeutics, expanding its leadership in oncology, strengthening its pipeline - Ipsen (OTC:IPSEY)
60% Left coverage: 10 sources
United States · United StatesOn Friday, the U.S. Food and Drug Administration (FDA) approved GSK Plc’s (NYSE:GSK) Blenrep (belantamab mafodotin-blmf) in combination with bortezomib and dexamethasone (BVd) for adult patients with relapsed or refractory multiple myeloma who have received at least two prior lines of therapy. The Blenrep approval is supported by data from the pivotal DREAMM-7 phase 3 trial. Multiple myeloma is the third most common blood cancer globally and is …See the Story
FDA Approves GSK's Withdrawn Blood Cancer Drug Blenrep - GSK (NYSE:GSK)
100% Center coverage: 1 sources
